Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Behind-The-Counter Guidance Stalled, But Interest Grows To Expand Access

This article was originally published in The Tan Sheet

Executive Summary

FDA executives say behind-the-counter status for nonprescription drugs resonates in discussions at the agency, but a former deputy commissioner says the agency's BTC interests are stifled by not having explicit authority
Advertisement

Related Content

CDER Director Sees Behind-The-Counter Switches As Best Bet
OTC Pseudoephedrine Purchases In Arkansas Require In-State Identification
Von Eschenbach Resigning In January With BTC Debate In His Legacy
Roche’s Flu MedKit Seeks “Alternate Pathway” For OTC Drugs
FDA Advisors Say Greater Insight Needed On Self-Selection Of OTC Statins
BTC Proponents Cite Pharmacists’ Role; Opponents Question Need
FDA Reauthorization Steers Clear Of Agency’s OTC Authority, DSHEA, AER Law
FDA Reauthorization Steers Clear Of Agency’s OTC Authority, DSHEA, AER Law
Von Eschenbach Promotes Behind-The-Counter Drug Class
Plan B Restrictions Set “Unique Example” Experts Say, But What May Follow?

Topics

Advertisement
UsernamePublicRestriction

Register

PS101812

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel